Related Experiment Video

Updated: Aug 6, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

[Fluvastatin affects HLA class I expression on endothelial cells]

Guillaume Belliard1, Stéphanie Coupel, Béatrice Charreau

  • 1Institut national de la santé et de la recherche médicale, UMR 643, Immunointervention en allo et xénotransplantation, et institut de transplantation et de recherche en transplantation, CHU Hôtel-Dieu, 44093 Nantes cedex 01, France.

Nephrologie & Therapeutique
|August 10, 2006
PubMed

Insights

Statins like fluvastatin can alter immune responses in endothelial cells (ECs). This study found fluvastatin upregulates MHC class I and downregulates MHC class II expression on ECs, potentially impacting vascular health.

Area of Science:

  • Immunology
  • Vascular Biology
  • Pharmacology

Background:

  • Statins, traditionally used for lipid management in atherosclerosis, may possess anti-inflammatory and immunomodulatory effects.
  • Previous research indicates statins can reduce MHC class II and CD40 expression on activated endothelial cells (ECs).

Purpose of the Study:

  • To investigate the impact of fluvastatin on Major Histocompatibility Complex (MHC) class I expression and regulation in human ECs.
  • To examine fluvastatin's effects on ECs in response to interferon-gamma (IFNγ).

Main Methods:

  • Primary human EC cultures were treated with varying doses of fluvastatin (0.01, 0.1, 1 µM) ± IFNγ for 48 hours.
  • Surface expression of MHC class I and class II was quantified using flow cytometry.
  • Reversal of effects was assessed using mevalonate.

Main Results:

  • Fluvastatin demonstrated a dose-dependent increase in MHC class I expression on quiescent ECs.
  • Fluvastatin enhanced IFNγ-induced MHC class I upregulation.
  • Fluvastatin inhibited IFNγ-induced MHC class II expression.
  • These statin-induced changes were reversible by mevalonate.

Conclusions:

  • Fluvastatin modulates MHC expression on ECs, upregulating MHC class I while downregulating MHC class II.
  • These findings suggest a potential role for statins in regulating immune responses within the vasculature.
  • Further in vitro and in vivo studies are needed to determine the functional significance of these statin-mediated MHC alterations on ECs.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...